Literature DB >> 8437500

[Value of adjuvant local antibiotic administration in therapy of open fractures. A comparative analysis of 704 consecutive cases].

P A Ostermann1, S L Henry, D Seligson.   

Abstract

Seven hundred and four compound fractures--198 (28%) grade I, 259 (37%) grade II, 247 (35%) grade III (86 IIIA, 119 IIIB, 42 IIIC)--were treated in 590 patients between May 1983 and May 1989 at the University of Louisville. Of these fractures, 157 (22%, group 1) received systemic antibiotic prophylaxis only, whereas 547 (78%, group 2) were treated with additional local application of aminoglycoside beads (tobramycin). Comparison of factors (fracture grades, age, sex, fracture location, follow up) revealed no significant differences between the two groups. All fractures underwent timely irrigation, debridement and skeletal stabilization. In group 1, 52 wounds were primarily closed, 53 underwent delayed primary closure and 52 were left open. In group 2 283 wounds were primarily closed, 229 were managed with the bead pouch technique and 35 were adapted loosely (delayed closure). Forty-nine (6.96%) of the 704 compound fractures became infected (acute wound infection and/or chronic osteomyelitis). Group 1 showed an infection rate of 16.6% (26/157), group 2 a rate of 4.2% (23/547). The difference was statistically highly significant (P < 0.001). Comparison of the infection rates, whether on an acute or a chronic basis, showed that infection rates were lower in group 2 than in group 1 for all fracture grades. A statistically significant difference was established only for type IIIB fractures, where the wound infection rate was 39.1% (9/23) in group 1 and 7.3% (7/96) in group 2 (P < 0.001). The rate of chronic osteomyelitis was 26.1% (6/23) in group 1 and 6.3% (6/96) in group 2 (P < 0.025).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437500     DOI: 10.1007/bf00207992

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  13 in total

1.  [Treatment of type II B open fracture--therapeutic regimen and results].

Authors:  P A Ostermann; A Ekkernkamp; S L Henry; D Seligson
Journal:  Zentralbl Chir       Date:  1992       Impact factor: 0.942

Review 2.  [Therapeutic strategies in fractures with soft tissue damage].

Authors:  G Muhr
Journal:  Chirurg       Date:  1991-05       Impact factor: 0.955

Review 3.  The management of open fractures.

Authors:  R B Gustilo; R L Merkow; D Templeman
Journal:  J Bone Joint Surg Am       Date:  1990-02       Impact factor: 5.284

4.  [Infection prevention and surgical management of deep insidious infection in total endoprosthesis].

Authors:  H W Buchholz; H D Gartmann
Journal:  Chirurg       Date:  1972-10       Impact factor: 0.955

Review 5.  Classification of type III (severe) open fractures relative to treatment and results.

Authors:  R B Gustilo; R P Gruninger; T Davis
Journal:  Orthopedics       Date:  1987-12       Impact factor: 1.390

6.  Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses.

Authors:  R B Gustilo; J T Anderson
Journal:  J Bone Joint Surg Am       Date:  1976-06       Impact factor: 5.284

7.  [Treatment of 2d and 3d degree complicated tibial shaft fractures with the PMMA bead pouch technic].

Authors:  P A Ostermann; S L Henry; D Seligson
Journal:  Unfallchirurg       Date:  1989-11       Impact factor: 1.000

8.  Experimental osteomyelitis: description of a canine model and the role of depot administration of antibiotics in the prevention and treatment of sepsis.

Authors:  R H Fitzgerald
Journal:  J Bone Joint Surg Am       Date:  1983-03       Impact factor: 5.284

9.  The role of early internal fixation in the management of open fractures.

Authors:  M W Chapman; M Mahoney
Journal:  Clin Orthop Relat Res       Date:  1979 Jan-Feb       Impact factor: 4.176

10.  Management of open tibial fractures.

Authors:  H S Byrd; T E Spicer; G Cierney
Journal:  Plast Reconstr Surg       Date:  1985-11       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.